Kalkine Media reports that Australian-based biotech Actinogen Medical, announced the registration of final patient into its placebo-controlled phase 2 Xanamem trial called XanADu. Developed by Actinogen, Xanamem is an inhibitor of 11β-hydroxysteroid dehydrogenase, an enzyme in the hypothalamic-pituitary-adrenal (HPA) axis of the body’s stress response. 11β-HSD1 converts the stress hormone cortisol to its active form, which binds to glucocorticoid receptors.  Actinogen is a small, publicly listed biotech.  See its annual shareholder report: https://actinogen.com.au/wp-content/uploads/2017/10/20171023-ASX-1729365-Annual-Report-to-Shareholders.pdf

Source: kalkine media

Pin It on Pinterest